Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 39
Summary
- Conditions
- Carcinoma of the Collecting Ducts of Bellini
- Chromophobe Renal Cell Carcinoma
- Kidney Medullary Carcinoma
- Kidney Oncocytoma
- Metastatic Renal Cell Cancer
- Papillary Renal Cell Carcinoma
- Recurrent Renal Cell Carcinoma
- Sarcomatoid Renal Cell Carcinoma
- Stage IV Renal Cell Cancer
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
PRIMARY OBJECTIVES: I. To determine the efficacy of pazopanib hydrochloride (pazopanib) in non clear cell metastatic renal cell cancer patients as assessed by the overall survival rate at 12 months. SECONDARY OBJECTIVES: I. To determine the rates of best tumor response at the end of the first two tr...
PRIMARY OBJECTIVES: I. To determine the efficacy of pazopanib hydrochloride (pazopanib) in non clear cell metastatic renal cell cancer patients as assessed by the overall survival rate at 12 months. SECONDARY OBJECTIVES: I. To determine the rates of best tumor response at the end of the first two treatment cycles of pazopanib in non clear cell metastatic renal cell cancer patients. II. To determine the benefit of pazopanib in increasing progression free survival time. III. To describe toxicity profile of pazopanib in non clear cell metastatic renal cell cancer patients. OUTLINE: Patients receive pazopanib hydrochloride orally (PO) once daily (QD) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for 2 years.
Tracking Information
- NCT #
- NCT01767636
- Collaborators
- National Cancer Institute (NCI)
- Investigators
- Principal Investigator: Brian Costello Mayo Clinic